Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application
Author:
Funder
National Natural Science Foundation of China
Natural Science Foundation of Jiangxi Province
Publisher
Elsevier BV
Subject
Pharmacology
Reference57 articles.
1. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor;Ayalasomayajula;Clin. Pharmacokinet.,2017
2. A test in context: neprilysin: function, inhibition, and biomarker;Bayes-Genis;J. Am. Coll. Cardiol.,2016
3. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation;Chang;J. Cardiol.,2019
4. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease;Cheung;Kidney Int.,2021
5. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides;D'Elia;Eur. J. Heart Fail.,2017
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis;Renal Failure;2024-06-13
2. Efficacy of Guideline-Directed Medical Therapy in Heart Failure Patients With and Without Chronic Kidney Disease: A Meta-Analysis of 63,677 Patients;Heart, Lung and Circulation;2024-03
3. Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease;Journal of Cardiovascular Pharmacology and Therapeutics;2024-01
4. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis;International Urology and Nephrology;2023-05-17
5. The effect of diminazene, an angiotensin‐converting enzyme 2 activator, on adenine‐induced chronic kidney disease in rats;Fundamental & Clinical Pharmacology;2022-11-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3